Insider transactions

EDGAR

ALLARITY THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–12 of 12

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-30 Filed 2026-10-09Graff Jeremy R. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)39,494——94,708Direct (D) No
F1
  • F1 Restricted stock units convert into common stock on a one-for-one basis.
Open filing 0001213900-26-108573 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-09Graff Jeremy R. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)14,6130.97
14,174.61

Derived: shares × price per share. Exact value 14174.61.

80,095Direct (D) No
F3, F5
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date.
  • F5 The 381,644 amount previously reported in column 5 of Table I of the Reporting Person's Form 4/A filed April 30, 2026 combined issued shares of common stock and unvested restricted stock units and did not reflect the 17,814 shares withheld on January 22, 2026. This Form 4 reports issued shares of common stock in Table I and unvested restricted stock units separately in Table II. After giving effect to the January 22, 2026 vesting and withholding and the January 28, 2026 restricted stock unit grant, the correct balances were 55,214 shares of common stock and 308,616 restricted stock units.
Open filing 0001213900-26-108573 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-09Graff Jeremy R. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (39,494)
Disposed (D)39,4940—269,122Direct (D) No
F1, F2, F4
  • F1 Restricted stock units convert into common stock on a one-for-one basis.
  • F2 On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.
  • F4 The amount reported in column 9 reflects 175,283 restricted stock units outstanding following the January 22, 2026 settlement, plus 133,333 restricted stock units granted on January 28, 2026 and previously reported, less 39,494 restricted stock units settled on September 30, 2026.
Open filing 0001213900-26-108573 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-05-14Jensen Thomas Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)200,0000—596,734Direct (D) No
F1
  • F1 The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
Open filing 0001213900-26-056373 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-05-07McLaughlin Gerald W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)45,0000—70,000Direct (D) No
F1
  • F1 The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.
Open filing 0001213900-26-053466 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-04-30Ervin Jeffrey S Officer: CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)150,0000—150,000Direct (D) No
F1
  • F1 The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
Open filing 0001213900-26-050131 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-04-30Graff Jeremy R. Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)133,3330—381,644Direct (D) No
F1
  • F1 The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
Open filing 0001213900-26-050133 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-10-09Graff Jeremy R. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)48,147——73,028Direct (D) No
F1
  • F1 Restricted stock units convert into common stock on a one-for-one basis.
Open filing 0001213900-26-108573 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-10-09Graff Jeremy R. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)17,8141.18
21,020.52

Derived: shares × price per share. Exact value 21020.52.

55,214Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date.
Open filing 0001213900-26-108573 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-10-09Graff Jeremy R. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (48,147)
Disposed (D)48,1470—175,283Direct (D) No
F1, F2
  • F1 Restricted stock units convert into common stock on a one-for-one basis.
  • F2 On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.
Open filing 0001213900-26-108573 Read from the filing’s XML Dispute this row
2026-01-07 Filed 2026-05-11Hoeiland Jesper Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.
Open filing 0001213900-26-054430 Read from the filing’s XML Dispute this row
2026-01-07 Filed 2026-01-16Graff Jeremy R. Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)133,3330—381,644Direct (D) No
F1
  • F1 The restricted stock units, or RSUs, granted on January 7, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
Open filing 0001213900-26-005146 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–20 of 20

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager304,800 SH320,040 dollarsLower by 26,709 Prior quarter: 331,509Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 171,795 SH180,385 dollarsUnchanged Prior quarter: 171,795Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager155,290 SH163,053 dollarsHigher by 423 Prior quarter: 154,867Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
STATE STREET CORP Partly reported under another manager154,800 SH162,540 dollarsHigher by 17,200 Prior quarter: 137,600Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD FIDUCIARY TRUST CO 74,913 SH78,659 dollarsUnchanged Prior quarter: 74,913Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Focus Partners Wealth 51,628 SH54,209 dollarsNot in the prior quarter’s filings read Open filing 0001542153-26-000021 Filed 2026-11-12 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager36,534 SH38,361 dollarsUnchanged Prior quarter: 36,534Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
HRT FINANCIAL LP 33,082 SH34 dollarsLower by 3,921 Prior quarter: 37,003Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
Virtu Financial LLC Partly reported under another manager26,282 SH28 dollarsHigher by 10,960 Prior quarter: 15,322Open filing 0001533964-26-000015 Filed 2026-11-17 Dispute this row
UBS Group AG Partly reported under another manager24,620 SH25,851 dollarsLower by 1,969 Prior quarter: 26,589Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
CITIGROUP INC Partly reported under another manager17,616 SH18,497 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
StoneX Group Inc. Partly reported under another manager17,388 SH18,794 dollarsNot in the prior quarter’s filings read Open filing 0000913760-26-000042 Filed 2026-11-03 Dispute this row
TWO SIGMA INVESTMENTS, LP 14,996 SH15,746 dollarsLower by 12,496 Prior quarter: 27,492Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager5,000 SH5,250 dollarsNot in the prior quarter’s filings read Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager4,352 SH4,570 dollarsHigher by 1,702 Prior quarter: 2,650Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Caitong International Asset Management Co., Ltd 23 SH24 dollarsHigher by 1 Prior quarter: 22Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
Robinhood Markets, Inc. 10 SH11 dollarsNot in the prior quarter’s filings read Open filing 0000950157-26-001278 Filed 2026-11-18 Dispute this row
BARCLAYS PLC Partly reported under another manager3 SH3 dollarsNot in the prior quarter’s filings read Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager1 SH1 dollarsUnchanged Prior quarter: 1Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
DANSKE BANK A/S 1 SH1 dollarsUnchanged Prior quarter: 1Open filing 0001104659-26-124081 Filed 2026-11-09 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Militia Capital Management LLC 98,978 SH
  • CITADEL ADVISORS LLC 91,748 SH
  • JANE STREET GROUP, LLC 36,021 SH
  • XTX Topco Ltd 20,884 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 17,221 SH
  • FMR LLC 13 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

No Schedule 13D or 13G naming this issuer is in the store; this is not a statement that none were filed.

What was read

2,687,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to ALLARITY THERAPEUTICS, INC.